News

Wednesday, 11. February 2026

News from akampion

We are pleased to announce that akampion has further strengthened its senior team with the addition of two highly experienced consultants — Francina Agosti, PhD, a trained neuroscientist, and Almut Gebhard, MSc, a trained biologist.

This move further expands akampion’s core strength: senior-level strategic communications advisory in situations where communications become truly value-critical — including financings, key data readouts, strategic milestones, leadership transitions, and early company-building phases.

Atopia Therapeutics Reports Preclinical Proof-of-Concept of Lead Compound ATP-R13 in Atopic Dermatitis and Strengthens Patent Protection

Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthma
Positive opinion from the European Patent Office strengthens patent protection of ATP-R13
Progress significantly enhances the strategic attractiveness of ATP-R13 as a broadly applicable, disease-modifying therapy across multiple allergic indications

Atopia Therapeutics, a leader in the development of innovative, disease-modifying therapies for allergic and atopic diseases, today announced significant progress in the development of its lead compound ATP-R13. The Company has successfully generated new preclinical in vivo efficacy data supporting the potential of ATP-R13 as a novel oral treatment for atopic dermatitis, an allergic condition commonly known as eczema.

Happy Holidays!

Thursday, 11. December 2025

Mabylon AG Initiates Phase I Clinical Trial of Lead Compound MY006 for the Treatment of Peanut Allergy

— First study participant dosed in U.S. trial with healthy volunteers and patients with peanut allergy

— Novel, human-derived, half-life extended tri-specific monoclonal antibody to prevent allergic reactions

Mabylon AG, a leader in the high-throughput discovery, engineering, and development of human-derived antibodies for the treatment of allergies, neurodegenerative diseases, and inflammation, today announced that the first healthy volunteer has been dosed in the first-in-human clinical trial evaluating MY006, a novel tri-specific monoclonal antibody for the prophylactic treatment of peanut allergy. MY006 is based on patient-derived antibodies and designed to provide a new approach for preventing allergic reactions in individuals with peanut allergy.